Activity Downloads

To Participate

To participate in this continuing education activity:

1. Review the activity description and objectives.
2. View the activity.
3. Complete the online post-test and activity evaluation.

View the other Modules in this CSPE Core Curriculum Series:
  
Cystic Fibrosis Module #1: Cystic Fibrosis: An Overview ►

Cystic Fibrosis Module #2: Chronic Medications: Changing the Course of Cystic Fibrosis ►

Cystic Fibrosis Module #3: Management of Acute Pulmonary Exacerbations: Pseudomonas and Beyond ►

 

This activity is available for free to members of NASP. Visit the top section of www.ProCE.com/CSPE for details.

A product of the National Association of Specialty Pharmacy's (NASP) Center for Specialty Pharmacy Education(CSPE). View more NASP/CSPE Activities►

Activity Description

Cystic Fibrosis (CF) is an inherited chronic disease caused by a gene defect. It is estimated to occur in about 1 in every 3500 children born in the United States. This complex disease can affect the lungs, the digestive system, and other organs resulting in a high morbidity and mortality. CF can also affect the pharmacokinetics of many drugs and this needs to be considered when prescribing medications to CF patients. CF has no known cure, but treatments are available to help modify the disease process. The modules of this program will provide information on the disease and treatments for the CF patient as well as address other important challenges and considerations in CF patients. Module 4 discusses the importance of adherence in CF patients and will address the role of education to improve the treatment of CF patients.

Target Audience

The target audience for this activity includes pharmacists and nurses.

Learning Objectives

Upon completion of this activity, participants will be able to:

• Describe medication adherence barriers faced by CF patients
• Explain features of innovative pharmacy-based management strategies that are associated with improving adherence, outcomes, and cost management in patients with CF
• Describe the medication access programs available for CF patients

Faculty

David Young, PharmD
Professor of Pharmacotherapy (Clinical)
PGY-2 Pharmacy Residency in Internal Medicine Director
University of Utah College of Pharmacy
Salt Lake City, Utah

CME/CE Accreditation

Pharmacist Release Date: May 15, 2020
Nurse Release Date: September 1, 2021
Expiration Date: May 15, 2023

ACPE Credit Designation (Pharmacist CE) This CE activity is jointly provided by ProCE, LLC and the National Association of Specialty Pharmacy (NASP). ProCE is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. ACPE Universal Activity Number 0221-9999-20-215-H01-P has been assigned to this knowledge-based, home-study activity. This CE activity is approved for 1.0 contact hour (0.1 CEU) in states that recognize ACPE providers. Completion of an evaluation and post-test with a score of 70% or higher is required to receive CE credit. Proof of completion will be posted in NABP CPE Monitor profiles. No partial credit will be given.

Joint Accreditation Statement In support of improving patient care, this activity has been planned and implemented by ProCE, LLC and Clinical Care Options, LLC (CCO). Clinical Care Options, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.   Nursing Continuing Education The maximum number of hours awarded for this Continuing Nursing Education activity is 1.0 contact hour.

Disclosure

It is the policy of ProCE, LLC to ensure balance, independence, objectivity and scientific rigor in all of its continuing education activities. Faculty must disclose to participants any significant financial interest or affiliation with companies that manufacture or market products discussed during their presentation.

Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty and planners reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:

David Young, PharmD has no relevant conflicts of interest to report.
CCO and ProCE Staff have no relevant conflicts of interest to report.
Robin Wanous-Williamson (nurse planner) has no relevant conflicts of interest to report.

Potential conflicts of interest were resolved with a peer review process provided by Robin Wanous-Williamson, RN, GERO-BC.

Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Funding

This activity is self-funded by NASP.

 

The material presented in this CE activity does not reflect the views of ProCE, LLC or the commercial sponsor. These materials may discuss uses and dosages for therapeutic products, processes, procedures and inferred diagnoses that have not been approved by the United States Food and Drug Administration. A qualified health care professional should be consulted before using any therapeutic product discussed. All readers and continuing education participants should verify all information and data before treating patients or employing any therapies described in this continuing education activity.